Fisetin and rutin as 3C protease inhibitors of enterovirus A71

Journal of Virological Methods

Volumn 182, Issue 1-2, 2012, Pages 93-98

  Lin, Ying Ju ^a,b   Chang, Yi Chih ^b   Hsiao, Nai Wan ^c   Hsieh, Jing Ling ^b,c   Wang, Ching Ying ^b   Kung, Szu Hao ^d   Tsai, Fuu Jen ^a,b   Lan, Yu Ching ^b   Lin, Cheng Wen ^b,e  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHANGHUA UNIVERSITY OF EDUCATION   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e ASIA UNIVERSITY   (Taiwan)

Author keywords

3C protease; Enterovirus A71; Fisetin; Flavonoids; Rutin

Indexed keywords

FISETIN; RUTOSIDE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ENTEROVIRUS 71; ENZYME ACTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN MOTIF; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; CYSTEINE ENDOPEPTIDASES; CYTOPATHOGENIC EFFECT, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENTEROVIRUS A, HUMAN; FLAVONOIDS; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; PROTEASE INHIBITORS; RUTIN; VIRAL LOAD; VIRAL PLAQUE ASSAY; VIRAL PROTEINS; VIRUS REPLICATION;

ENTEROVIRUS;

EID: 84860009671     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2012.03.020     Document Type: Article

References (38)

1. Benavente G.O., Castillo J. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J. Agric. Food Chem. 2008, 56:6185-6205.
2. Binford S.L., Maldonada F., Brothers M.A., Weady P.T., Zalman L.S., Meador J.W., Matthews D.A., Patick A.K. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob. Agents Chemother. 2005, 49:619-626.
3. Binford S.L., Weady P.T., Maldonado F., Brothers M.A., Matthews D.A., Patick A.K. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 2007, 51:4366-4373.
4. Castrillo J.L., Vanden B.D., Carrasco L. 3-Methylquercetin is a potent and selective inhibitor of poliovirus RNA synthesis. Virology 1986, 152:219-227.
5. Chang L.Y., Lin T.Y., Hsu K.H., Huang Y.C., Lin K.L., Hsueh C., Shih S.R., Ning H.C., Hwang M.S., Wang H.S., Lee C.Y. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 1999, 354:1682-1686.
6. Chen T.C., Weng K.F., Chang S.C., Lin J.Y., Huang P.N., Shih S.R. Development of antiviral agents for enteroviruses. J. Antimicrob. Chemother. 2008, 62:1169-1173.
7. Chen T.C., Chang H.Y., Lin P.F., Chern J.H., Hsu J.T., Chang C.Y., Shih S.R. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob. Agents Chemother. 2009, 53:2740-2747.
8. Chu S.C., Hsieh Y.S., Lin J.Y. Inhibitory effects of flavonoids on Moloney murine leukemia virus reverse transcriptase activity. J. Nat. Prod. 1992, 55:179-183.
9. Conti C., Tomao P., Genovese D., Desideri N., Stein M.L., Orsi N. Mechanism of action of the antirhinovirus flavanoid 4',6-dicyanoflavan. Antimicrob. Agents Chemother. 1992, 36:95-99.
10. Conti C., Genovese D., Santoro R., Stein M.L., Orsi N., Fiore L. Activities and mechanisms of action of halogen-substituted flavanoids against poliovirus type 2 infection in vitro. Antimicrob. Agents Chemother. 1990, 34:460-466.
11. Dragovich P.S., Webber S.E., Babine R.E., Fuhrman S.A., Patick A.K., Matthews D.A., Reich S.H., Marakovits J.T., Prins T.J., Zhou R., Tikhe J., Littlefield E.S., Bleckman T.M., Wallace M.B., Little T.L., Ford C.E., Meador J.W., Ferre R.A., Brown E.L., Binford S.L., DeLisle D.M., Worland S.T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J. Med. Chem. 1998, 41:2819-2834.
12. Genovese D., Conti C., Tomao P., Desideri N., Stein M.L., Catone S., Fiore L. Effect of chloro-, cyano-, and amidino-substituted flavanoids on enterovirus infection in vitro. Antiviral Res. 1995, 27:123-136.
13. Ho M., Chen E.R., Hsu K.H., Twu S.J., Chen K.T., Tsai S.F., Wang J.R., Shih S.R. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N. Engl. J. Med. 1999, 341:929-935.
14. Huang C.C., Liu C.C., Chang Y.C., Chen C.Y., Wang S.T., Yeh T.F. Neurologic complications in children with enterovirus 71 infection. N. Engl. J. Med. 1999, 341:936-942.
15. Hung H.C., Wang H.C., Shih S.R., Teng I.F., Tseng C.P., Hsu J.T. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J. Infect. Dis. 2011, 203:1784-1790.
16. Kuo C.J., Shie J.J., Fang J.M., Yen G.R., Hsu J.T., Liu H.G., Tseng S.N., Chang S.C., Lee C.Y., Shih S.R., Liang P.H. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg. Med. Chem. 2008, 16:7388-7398.
17. Lei X., Sun Z., Liu X., Jin Q., He B., Wang J. Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated by Toll-like receptor 3. J. Virol. 2011, 85:8811-8818.
18. Lin T.Y., Twu S.J., Ho M.S., Chang L.Y., Lee C.Y. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg. Infect. Dis. 2003, 9:291-293.
19. Lin K.H., Hwang K.P., Ke G.M., Wang C.F., Ke L.Y., Hsu Y.T., Tung Y.C., Chu P.Y., Chen B.H., Chen H.L., Kao C.L., Wang J.R., Eng H.L., Wang S.Y., Hsu L.C., Chen H.Y. Evolution of EV-A71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV-A71. J. Med. Virol. 2006, 78:254-262.
20. Lu G., Qi J., Chen Z., Xu X., Gao F., Lin D., Qian W., Liu H., Jiang H., Yan J., Gao G.F. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J. Virol. 2011, 85:10319-10331.
21. Lyu S.Y., Rhim J.Y., Park W.B. Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. Arch. Pharm. Res. 2005, 28:1293-1301.
22. Manthey J.A., Grohmann K., Guthrie N. Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr. Med. Chem. 2001, 8:135-153.
23. Matthews D.A., Dragovich P.S., Webber S.E., Fuhrman S.A., Patick A.K., Zalman L.S., Hendrickson T.F., Love R.A., Prins T.J., Marakovits J.T., Zhou R., Tikhe J., Ford C.E., Meador J.W., Ferre R.A., Brown E.L., Binford S.L., Brothers M.A., DeLisle D.M., Worland S.T. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:11000-11007.
24. Mizuta K., Aoki Y., Suto A., Ootani K., Katsushima N., Itagaki T., Ohmi A., Okamoto M., Nishimura H., Matsuzaki Y., Hongo S., Sugawara K., Shimizu H., Ahiko T. Cross-antigenicity among EV-A71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 2009, 27:3153-3158.
25. Orhan D.D., Ozcelik B., Ozgen S., Ergun F. Antibacterial, antifungal, and antiviral activities of some flavonoids. Microbiol. Res. 2010, 165:496-504.
26. Panasiak W., Wleklik M., Oraczewska A., Luczak M. Influence of flavonoids on combined experimental infections with EMC virus and Staphylococcus aureus in mice. Acta Microbiol. Pol. 1989, 38:185-188.
27. Patick A.K., Binford S.L., Brothers M.A., Jackson R.L., Ford C.E., Diem M.D., Maldonado F., Dragovich P.S., Zhou R., Prins T.J., Fuhrman S.A., Meador J.W., Zalman L.S., Matthews D.A., Worland S.T. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 1999, 43:2444-2450.
28. Pallansch M.A., Roos R. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. Fields Virology 2007, 839-893. Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
29. Pawlotsky J.M., Chevaliez S., McHutchison J.G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007, 132:1979-1998.
30. Rivera C.I., Lloyd R.E. Modulation of enteroviral proteinase cleavage of poly(A)-binding protein (PABP) by conformation and PABP-associated factors. Virology 2008, 375:59-72.
31. Salvati A.L., Dominicis D.A., Tait S., Canitano A., Lahm A., Fiore L. Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus. Antimicrob. Agents Chemother. 2004, 48:2233-2243.
32. Singh S., Poh C.L., Chow V.T. Complete sequence analyses of enterovirus 71 strains from fatal and non-fatal cases of the hand, foot and mouth disease outbreak in Singapore. Microbiol. Immunol. 2002, 46:801-808.
33. Spouge J.L. Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:7581-7585.
34. Tao J., Hu Q., Yang J., Li R., Li X., Lu C., Chen C., Wang L., Shattock R., Ben K. In vitro anti-HIV and -HSV activity and safety of sodium rutin sulfate as a microbicide candidate. Antiviral Res. 2007, 75:227-233.
35. Tsai M.T., Cheng Y.H., Liu Y.N., Liao N.C., Lu W.W., Kung S.H. Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer. Antimicrob. Agents Chemother. 2009, 53:748-755.
36. Weng K.F., Li M.L., Hung C.T., Shih S.R. Enterovirus 71 3C protease cleaves a novel target CstF-64 and inhibits cellular polyadenylation. PLoS Pathog. 2009, 5:e1000593.
37. Yang F., Ren L., Xiong Z., Li J., Xiao Y., Zhao R., He Y., Bu G., Zhou S., Wang J., Qi J. Enterovirus 71 outbreak in the People's Republic of China in 2008. J. Clin. Microbiol. 2009, 47:2351-2352.
38. Zuo G.Y., Li Z.Q., Chen L.R., Xu X.J. In vitro anti-HCV activities of Saxifraga melanocentra and its related polyphenolic compounds. Antivir. Chem. Chemother. 2005, 16:393-398.